Protocol Title: Efficacy and safety of cagrilintide s.c. 2.4 mg in combination with semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) once-weekly in participants with overweight or obesity (Study ID: NN9838-4608)
Participants will be randomly assigned to one of four treatment options (CagriSema, or Cagrilintide alone, Semaglutide alone, or placebo) and will receive monthly dietary counseling during the 75 week main study.
Participants must be: -18 years or older -Have a BMI of 30 or greater (or a BMI of 27 or greater with high blood pressure, high cholesterol, sleep apnea or cardiovascular disease) -NOT have type 1 or 2 diabetes
Anschutz Health and Wellness
Daniel Bessesen, MD
Protocol Number: 22-1393
More information available at ClinicalTrials.gov: NCT05567796
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers